Innoviva, Inc.(INVA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #136 of 2,879 stocksTOP 5%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
INVA Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Innoviva, Inc. (INVA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INVA at 75.2/100 on a 32-signal composite quality model, placing it at rank #136 of 2,879 stocks — the top 5% of the AI-ranked universe. INVA scores in the top quartile across profitability (96.1), balance sheet strength (95.5), free cash flow (91.5). Areas of concern include revenue scale (33.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 38.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Innoviva, Inc. reports quarterly revenue of $98.0M, net income of $186.6M, an operating margin of 38.9%. Top institutional holders of INVA by reported 13-F value include BlackRock,, DIMENSIONAL FUND ADVISORS, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. INVA trades on the Nasdaq exchange and files with the SEC under CIK 1080014. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INVA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Innoviva, Inc. directly from SEC EDGAR. Innoviva, Inc.'s 13F Pro composite quality score has ranged between 8 and 76 since 2021, currently 75.2 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.
What's Driving INVA's Business? Latest 10-Q Breakdown
AI-extracted from Innoviva, Inc.'s 10-Q filed 2026-05-06 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Q1 2026 net income surged to $186.6M ($2.52 EPS) driven by $157.7M unrealized gain on Armata equity holdings and 37% growth in net product sales to $41.4M.
Biggest Revenue Drivers
Total revenue: $98.0M+11% YoY
Lower net sales from RELVAR/BREO ELLIPTA due to U.S. pricing pressures, partially offset by ANORO ELLIPTA growth.
Growth driven by GIAPREZA (+14% U.S.), XACDURO (+99% U.S., +230% ex-US from Zai Lab interim supply), and ZEVTERA launch.
Derived primarily from ongoing Zai Lab arrangements including manufacturing transfer services and interim supply.
Largest Expense Items
Increased due to commercialization efforts for critical care products and regulatory compliance.
Higher product sales volume and $1.1M inventory fair value step-up from La Jolla acquisition.
Amortization of intangible assets from Entasis and La Jolla acquisitions.
Additional personnel and facilities costs supporting acquired IPR&D from Lyndra asset acquisition.
Watch Items from the Filing
- GSK royalty concentration: Gross royalty revenue of $58.6M (59% of total revenue) declined 5% YoY; near-term success dependent on GSK's commercialization of RELVAR/BREO and ANORO in competitive market.
- Three customers each represent 27%, 25%, and 25% of net product sales (Q1 2026); customer concentration risk in specialty distributor network for hospital products.
- Armata investment valued at $603.4M (33% of total assets) as of March 31, 2026 with 68.4% ownership; $157.7M unrealized Q1 gain creates significant fair value volatility exposure.
- 2028 convertible notes mature March 15, 2028; $261M principal outstanding with $13.9M remaining future interest; potential dilution if converted.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Revenue
Q1 2026
$98.0M
Net Income
Q1 2026
$186.6M
Free Cash Flow
Q1 2026
$34.8M
Operating Margin
Q1 2026
38.9%
D/E Ratio
Q1 2026
0.19
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+14.7% YoYOperating Income
-1.9% YoYEPS (Diluted)
+816.7% YoYTotal Assets
+25.7% YoYTotal Debt
-42.5% YoYOp. Cash Flow
+4.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $411.3M +14.7% | $358.7M +15.5% | $310.5M -20.8% | $391.9M +16.4% | $336.8M +29.0% | $261.0M |
| Operating Income | $163.7M -1.9% | $166.9M +46.5% | $113.9M -69.6% | $375.1M +16.8% | $321.1M +30.3% | $246.4M |
| EPS (Diluted) | $3.30 +816.7% | $0.36 -83.6% | $2.20 -23.3% | $2.87 +42.1% | $2.02 +41.3% | $1.43 |
| Total Assets | $1.64B +25.7% | $1.30B +4.6% | $1.24B +34.2% | $926.4M -7.3% | $999.6M +37.9% | $724.8M |
| Total Debt | $257.7M -42.5% | $448.3M +0.5% | $446.2M +13.1% | $394.7M +2.4% | $385.5M +2.2% | $377.1M |
| Operating Cash Flow | $196.9M +4.4% | $188.7M +33.8% | $141.1M -61.2% | $363.8M +16.2% | $313.1M +21.6% | $257.5M |
Get alerted when INVA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Innoviva, Inc. including:
Top Institutional Holders of INVA
BlackRock, Inc.
$263.5M11,307,845 shDIMENSIONAL FUND ADVISORS LP
$103.4M4,436,427 shVANGUARD PORTFOLIO MANAGEMENT LLC
$98.4M4,224,951 shRENAISSANCE TECHNOLOGIES LLC
$94.5M4,055,632 shVANGUARD CAPITAL MANAGEMENT LLC
$73.2M3,141,581 shSTATE STREET CORP
$71.3M3,060,377 shMILLENNIUM MANAGEMENT LLC
$53.1M2,279,451 shSarissa Capital Management LP
$49.7M2,130,950 shSYSTEMATIC FINANCIAL MANAGEMENT LP
$47.2M2,024,082 shLINDEN ADVISORS LP
$46.0M42,396,000 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $263.5M | 11,307,845 |
| DIMENSIONAL FUND ADVISORS LP | $103.4M | 4,436,427 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $98.4M | 4,224,951 |
| RENAISSANCE TECHNOLOGIES LLC | $94.5M | 4,055,632 |
| VANGUARD CAPITAL MANAGEMENT LLC | $73.2M | 3,141,581 |
| STATE STREET CORP | $71.3M | 3,060,377 |
| MILLENNIUM MANAGEMENT LLC | $53.1M | 2,279,451 |
| Sarissa Capital Management LP | $49.7M | 2,130,950 |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | $47.2M | 2,024,082 |
| LINDEN ADVISORS LP | $46.0M | 42,396,000 |
More Healthcare Companies
View all Healthcare →Put INVA on your watchlist
Track score changes the day Innoviva, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is INVA a good stock to buy?
13F Pro's AI-powered analysis of Innoviva, Inc. (INVA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INVA are available on the INVA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own INVA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INVA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Innoviva, Inc.'s investment landscape.